Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
about
Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot studyGenome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastomaEpigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge.Two independent epigenetic biomarkers predict survival in neuroblastomaMethylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance.Pediatric cancer epigenome and the influence of folateModulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs.Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumorsEpigenetic changes in pediatric solid tumors: promising new targets.Epigenetics, nervous system tumors, and cancer stem cells.MicroRNA-23a promotes neuroblastoma cell metastasis by targeting CDH1.Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells.MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines.Neuroblastoma cells negative for CD44 possess tumor-initiating properties.Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease
P2860
Q28729757-03AD6147-341F-4584-8EB0-0AA1DA930FEDQ33578303-392A1F38-9A2F-4039-B89C-3FF389ED5F24Q33709840-01403F90-D878-4F65-9B8C-8749381277CEQ34416570-FF39F9E9-2436-4862-AABC-7DD3F7C10D81Q34420371-5B4083BE-21C6-463D-8A49-800D1B494FAAQ34442835-E1CBFE27-CB41-4B96-B3DF-8B15E95E1BBCQ34743908-20490BFE-729D-4CA5-9F44-35D310296CFDQ35170598-31EE4B7D-190F-412D-868C-2A884E734CAAQ35208036-F103C4B9-46B4-461A-AE1B-4F516CC3266FQ36259607-7770A058-D2EA-4E0A-BE4B-BC2B6A5C8EB7Q36335774-F522122A-995A-4EAB-B80D-D24CEEBF887EQ36378134-FAE290F3-6FE2-4EC8-A9D4-462B21250432Q36838937-B9091FB6-76C5-4451-8489-A5C437D42A98Q36953153-1C3C77FA-2A98-46B8-9EE6-90229B323C85Q37137442-5E6A90D0-79D2-4413-97EC-F718541B76DDQ37574731-74E045A6-7C6D-4004-8A06-2C20253F9D2FQ38474631-0A951691-7FF3-412F-BD37-2C63B4DCD72DQ39449319-3BC2BB7D-9E86-4947-9B4E-61A8552B543FQ42089520-454AC701-8D69-4441-A164-841BC810A1B0Q48874456-D014DC2F-9E45-4C29-8EFE-300BD1CDEBCFQ51334063-5D5278B7-1AE9-4A50-AD11-DAA131ADE128Q51534604-CA68EC56-763A-4995-A77B-431B06643D2FQ53098086-544C10B3-FCF9-4D6F-B5B1-16C6B57D0DEBQ53259901-A3C0BE85-F1B4-4CC2-B655-1B1480AC3A2FQ57732371-EB8D54DA-3ECD-4E51-B0AA-5D145B161946
P2860
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
@en
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
@nl
type
label
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
@en
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
@nl
prefLabel
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
@en
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
@nl
P2093
P50
P1433
P1476
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
@en
P2093
Anne De Paepe
Claire Hoyoux
Evi Michels
Geneviève Laureys
Jasmien Hoebeeck
Joëlle Vermeulen
Nurten Yigit
Valérie Combaret
P304
P356
10.1016/J.CANLET.2008.08.019
P407
P577
2008-09-25T00:00:00Z